Who Might Benefit from GLP-1 Medications
Kittleson MD, Keene B, Pion PD, Loyer CG
Wellness clinics offering IV glutathione without individualized prescriptions operate in a regulatory gap the FDA monitors through warning letters but has not systematically shut down
In the 72-week study of more than 1,600 overweight or obese adults with Type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds, versus 2.2% for those who received a placebo, achieving the main goal of the trial
However, patients should verify individual provider qualifications, as telehealth platforms vary in the depth of subspecialty training or obesity-medicine certification among their networks